When Dr. Hans Hammers reviewed the latest results from the LITESPARK-022 trial at UT Southwestern Medical Center in Dallas, he saw something rare in cancer research: a clear step forward for patients who’ve already endured surgery for aggressive kidney cancer. The U.S. Food and Drug Administration has now approved Merck’s Welireg (belzutifan) in combination with pembrolizumab—or pembrolizumab with berahyaluronidase alfa-pmph (Keytruda Qlex)—for adults with renal cell carcinoma containing a clear cell component who are at intermediate-high or high risk of recurrence after nephrectomy, or after surgery to remove both the primary tumor and metastatic lesions. This approval marks a pivotal shift for adjuvant therapy in kidney cancer, a disease that affects over 80,000 Americans annually and remains challenging to treat once it returns.
Kidney cancer, particularly the clear cell subtype, has long relied on immune checkpoint inhibitors like pembrolizumab to prevent recurrence. But until now, adding another agent to boost protection had not shown consistent success. The LITESPARK-022 trial changed that. Conducted across 285 sites worldwide, the Phase III study followed patients for a median of 28.4 months and found that those receiving Welireg alongside pembrolizumab had a 28% lower risk of disease recurrence compared to those on pembrolizumab with placebo. The numbers were striking: 186 disease-free survival events occurred in the Welireg combination group versus 246 in the control group, a statistically significant improvement confirmed at a prespecified interim analysis. While median disease-free survival was not yet reached in either group, the direction of progress is clear.
The biological rationale behind the combination lies in Welireg’s unique mechanism. Belzutifan, the active ingredient, inhibits HIF-2α, a protein that fuels tumor growth in clear cell renal cell carcinoma due to the frequent loss of the VHL gene. By targeting this pathway and pairing it with pembrolizumab’s immune-activating effects, the therapy strikes at both the tumor’s engine and the body’s ability to fight it. Still, the treatment is not without risks. Welireg carries a boxed warning for embryo-fetal toxicity, along with precautions for anemia and hypoxia, while pembrolizumab warns of immune-mediated adverse reactions and infusion-related complications.
For the thousands of patients facing uncertain outcomes after kidney cancer surgery, this approval offers more than a new drug—it offers time. Time without recurrence. Time to return to work, to family, to life. Though overall survival data remain immature, the DFS improvement is a strong signal of benefit. As research continues and longer-term results emerge, this combination may become a new standard for high-risk patients. In the evolving landscape of precision oncology, where each advance builds on the last, this moment stands as a quiet but powerful victory.